News|Articles|December 29, 2025

Top 5 oncology news articles of 2025

Listen

0:00 / 0:00

Key Takeaways

CAR T-cell therapy reduces costs and treatment duration in mantle cell lymphoma compared to standard care.
Oncologists face challenges integrating new cancer treatments, necessitating better tools and education.
ELI-002 2P cancer vaccine shows potential in boosting immune responses and survival in colorectal and pancreatic cancers.
Medicare Advantage plans are less likely to utilize low-value cancer treatments.
Prior authorizations create barriers and delays in accessing cancer medications, according to oncologists.

Breakthrough treatments, shifting care models and persistent system challenges defined cancer care this year, from evidence that CAR T-cell therapy can lower costs and treatment burden in mantle cell lymphoma to promising off-the-shelf cancer vaccines.

1. CAR T-Cell therapy cuts costs, reduces treatment in mantle cell lymphoma

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.

2. Survey reveals cancer doctors struggle to keep up as treatments advance quickly

A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.

3. Off-the-shelf cancer vaccine shows promise in colorectal and pancreatic cancer patients

Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer patients, enhancing survival rates.

4. Medicare advantage less likely to use low-value cancer treatments, study finds

Medicare Advantage, an alternative to traditional Medicare that offers beneficiaries private health plan options, has grown substantially in the past ten years. In 2024, 54% of individuals with Medicare were enrolled in Medicare Advantage.

5. Oncologists: prior authorizations lead to delays in getting cancer meds

Insurance hurdles and the complexities of prior authorization create barriers to care, according to oncologists in a new survey by Sermo.